Clinical and histopathological profile of patients with multiple myeloma and renal involvement

Main Article Content

Manjuri Sharma https://orcid.org/0000-0002-4859-5272
Arunima Mahanta
Jina Bhattacharyya

Keywords

Acute kidney injury; Amyloidosis; Chronic kidney disease; Multiple myeloma; Myeloma cast nephropathy

Abstract

Background: Multiple Myeloma (MM) is a malignant disorder of plasma cell characterised by the clonal expansion of aberrant plasma cells within the bone marrow. This leads to the excessive production of monoclonal immunoglobulins (M-protein) and associated with organ dysfunction. Renal disease is a frequent and a potentially significant complication of multiple myeloma. The range of renal lesions observed in the patients with multiple myeloma is diverse. The aim of present study is to find the clinical and histopathological profile of patients with multiple myeloma and renal involvement and their clinico-pathological correlation. Methods: This was an observational hospital based study where 33 patients with multiple myeloma as well as renal involvement who agreed for renal biopsy were included. Demographic data, mode of presentation and need for dialysis were noted. Appropriate laboratory tests and radiological survey were done. Results: The median age of the patients in our study was 56 years. Fatigue was the most common clinical feature. The indications for renal biopsy were acute kidney injury (AKI), chronic/progressive reduction in glomerular filtration rate (GFR) with normal sized kidneys and nephrotic syndrome. Histopathological findings in the patients with acute kidney injury included myeloma cast nephropathy, acute tubulointerstitial nephropathy, acute tubular necrosis and IgA (Immunoglobulin A) nephropathy. In cases with chronic decline in GFR, observed lesions were myeloma cast nephropathy, monoclonal immunoglobulin deposition disease, membranoproliferative glomerulonephritis, chronic interstitial nephropathy and diabetic nephropathy. For patients presenting with nephrotic syndrome, amyloidosis and monoclonal immunoglobulin deposition disease were predominant. Conclusions: Renal involvement is considered as one of the main feature of multiple myeloma and is often the initial manifestation of the disease. Renal biopsy is crucial for establishing a specific diagnosis and providing valuable prognostic and therapeutic insights.

Abstract 3 | PDF Downloads 1 HTML Downloads 0 XML Downloads 1

References

[1] Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J. Renal function in newly diagnosed multiple myeloma—a demographic study of 1353 patients. European Journal of Haematology. 1994; 53: 207–212.
[2] Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings. 2003; 78: 21–33.
[3] Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. European Journal of Haematology. 2000; 65: 175–181.
[4] Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008; 22: 1485–1493.
[5] Stompór T, Zabłocki M, Pankrac K. Renal involvement in multiple myeloma. Polish Archives of Internal Medicine. 2012; 122: 443–448.
[6] Bora K. Distribution of multiple myeloma in India: heterogeneity in incidence across age, sex and geography. Cancer Epidemiology. 2019; 59: 215–220.
[7] Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. Journal of Clinical Oncology. 2005; 23: 3412–3420.
[8] Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The Lancet Oncology. 2014; 15: e538–e548.
[9] Haynes RJ, Read S, Collins GP, Darby SC, Winearls CG. Presentation and survival of patients with severe acute kidney injury and multiple myeloma: a 20-year experience from a single centre. Nephrology Dialysis Transplantation. 2010; 25: 419–426.
[10] Prakash J, Niwas SS, Parekh A, Vohra R, Wani IA, Sharma N, et al. Multiple myeloma—presenting as acute kidney injury. Journal of Association of Physicians of India. 2009; 57: 23–26.
[11] Sakhuja V, Jha V, Varma S, Joshi K, Gupta KL, Sud K, et al. Renal involvement in multiple myeloma: a 10-year study. Renal Failure. 2000; 22: 465–477.
[12] Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB, et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. Journal of the American Society of Nephrology. 2001; 12: 1482–1492.
[13] Nasr SH, Valeri AM, Sethi S, Fidler ME, Cornell LD, Gertz MA, et al. Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies. American Journal of Kidney Diseases. 2012; 59: 786–794.
[14] Zand L, Kattah A, Fervenza FC, Smith RJ, Nasr SH, Zhang Y, et al. C3 glomerulonephritis associated with monoclonal gammopathy: a case series. American Journal of Kidney Diseases. 2013; 62: 506–514.
[15] Blade J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Archives of Internal Medicine. 1998; 158: 1889–1893.
[16] Yadav P, Cook M, Cockwell P. Current trends of renal impairment in multiple myeloma. Kidney Diseases. 2016; 1: 241–257.
[17] Badri VK, Badri PR, Gupta A. Renal failure in multiple myeloma: the role of plasmapheresis and chemotherapy on reversibility and prognosis—a single center experience from India. International Journal of Academic Medicine and Pharmacy. 2022; 4: 9–18.
[18] Pozzi C, Pasquali S, Donini U, Casanova S, Banfi G, Tiraboschi G, et al. Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Report of the Italien Renal Immunopathology Group. Clinical Nephrology. 1987; 28: 1–9.
[19] Shankar M, Anandh U, Guditi S. Multiple facets of multiple myeloma in kidney biopsy: a multicenter retrospective study. Indian Journal of Nephrology. 2024; 34: 31–36.
[20] Leung N, Rajkumar SV. Multiple myeloma with acute light chain cast nephropathy. Blood Cancer Journal. 2023; 13: 1–7.
[21] Dimopoulos MA, Merlini G, Bridoux F, Leung N, Mikhael J, Harrison SJ, et al. Management of multiple myeloma—related renal impairment: recommendations from the International Myeloma Working Group. The Lancet Oncology. 2023; 24: e293–e311.
[22] Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E, et al. International Myeloma Working Group Recommendations for the diagnosis and management of Myeloma—related renal impairment. Journal of Clinical Oncology. 2016; 34: 1544–1557.
[23] Montseny JJ, Kleinknecht D, Meyrier A, Vanhille P, Simon P, Pruna A, et al. Long-term outcome according to renal histological lesions in 118 patients with monoclonal gammopathies. Nephrology Dialysis Transplantation. 1998; 13: 1438–1445.
[24] Gonsalves WI, Leung N, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, et al. Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma. Blood Cancer Journal. 2015; 5: e296.
[25] Yadav P, Hutchison CA, Basnayake K, Stringer S, Jesky M, Fifer L, et al. Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury. European Journal of Haematology. 2016; 96: 610–617.